BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stone GW, Kimura T, Gao R, Kereiakes DJ, Ellis SG, Onuma Y, Chevalier B, Simonton C, Dressler O, Crowley A, Ali ZA, Serruys PW. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. JAMA Cardiol 2019;4:1261-9. [PMID: 31561250 DOI: 10.1001/jamacardio.2019.4101] [Cited by in Crossref: 42] [Cited by in F6Publishing: 24] [Article Influence: 42.0] [Reference Citation Analysis]
Number Citing Articles
1 Polimeni A, Sorrentino S, Spaccarotella C, Mongiardo A, Sabatino J, De Rosa S, Gori T, Indolfi C. Stent Thrombosis After Percutaneous Coronary Intervention: From Bare-Metal to the Last Generation of Drug-Eluting Stents. Cardiol Clin 2020;38:639-47. [PMID: 33036724 DOI: 10.1016/j.ccl.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Koh JS, Gogas BD, Kumar S, Benham JJ, Sur S, Spilias N, Kumar A, Giddens DP, Rapoza R, Kereiakes DJ, Stone G, Jo H, Samady H. Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug-eluting stents. Catheter Cardiovasc Interv 2021. [PMID: 34164905 DOI: 10.1002/ccd.29819] [Reference Citation Analysis]
3 Kearney A, Linden K, Savage P, Menown IBA. Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials. Adv Ther 2021;38:2170-200. [PMID: 33844133 DOI: 10.1007/s12325-021-01711-z] [Reference Citation Analysis]
4 Wu Y, Yin J, Chen J, Yao Z, Qian J, Shen L, Ge L, Ge J. Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single de novo coronary lesions in a first-in-human study. Ann Transl Med 2020;8:1162. [PMID: 33241011 DOI: 10.21037/atm-20-5668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Nappi F, Nenna A, Larobina D, Martuscelli G, Singh SSA, Chello M, Ambrosio L. The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy. Polymers (Basel) 2021;13:446. [PMID: 33573282 DOI: 10.3390/polym13030446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Masiero G, Rodinò G, Boiago M, Matsuda Y, Tarantini G. Bioresorbable Scaffolds in Percutaneous Coronary Intervention: Facing Old Problems, Raising New Hopes. Curr Cardiol Rep 2021;23:15. [PMID: 33495895 DOI: 10.1007/s11886-021-01447-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Räber L, Ueki Y. Understanding the Bioresorbable Vascular Scaffold Achilles Heel. JACC: Cardiovascular Interventions 2020;13:128-31. [DOI: 10.1016/j.jcin.2019.10.049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kawashima H, Ono M, Kogame N, Takahashi K, Chang C, Hara H, Gao C, Wang R, Tomaniak M, Modolo R, Wykrzykowska JJ, De Winter RJ, Sharif F, Serruys PW, Onuma Y. Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update. Expert Opinion on Drug Delivery 2020;17:931-45. [DOI: 10.1080/17425247.2020.1764932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Melnick G, Ferrone M, Cheng Y, Conditt GB, Guérios ÊE, Rousselle SD, Granada JF, Kaluza GL. Long-term performance and biocompatibility of a novel bioresorbable scaffold for peripheral arteries: A three-year pilot study in Yucatan miniswine. Catheter Cardiovasc Interv 2020;95:1277-84. [PMID: 32105408 DOI: 10.1002/ccd.28810] [Reference Citation Analysis]
10 Ochijewicz D, Tomaniak M, Opolski G, Kochman J. Inflammation as a determinant of healing response after coronary stent implantation. Int J Cardiovasc Imaging 2021;37:791-801. [PMID: 33479786 DOI: 10.1007/s10554-020-02073-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Włodarczak A, Łanocha M, Szudrowicz M, Barycki M, Gosiewska A, Kulczycki JJ, Lesiak M, Doroszko A, Rola P. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome. J Clin Med 2021;10:3166. [PMID: 34300332 DOI: 10.3390/jcm10143166] [Reference Citation Analysis]
12 Kawashima H, Zocca P, Buiten RA, Smits PC, Onuma Y, Wykrzykowska JJ, de Winter RJ, von Birgelen C, Serruys PW. The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective. Neth Heart J 2020;28:78-87. [PMID: 32780336 DOI: 10.1007/s12471-020-01442-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Haude M, Toelg R, Lemos PA, Christiansen EH, Abizaid A, von Birgelen C, Neumann FJ, Wijns W, Ince H, Kaiser C, Lim ST, Escaned J, Eeckhout E, Garcia-Garcia HM, Waksman R. Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the BIOSOLVE-II first-in-man trial at 5 years. Cardiovasc Revasc Med 2021:S1553-8389(21)00544-3. [PMID: 34364807 DOI: 10.1016/j.carrev.2021.07.017] [Reference Citation Analysis]
14 Wu X, Wu S, Kawashima H, Hara H, Ono M, Gao C, Wang R, Lunardi M, Sharif F, Wijns W, Serruys PW, Onuma Y. Current perspectives on bioresorbable scaffolds in coronary intervention and other fields. Expert Rev Med Devices 2021;18:351-65. [PMID: 33739213 DOI: 10.1080/17434440.2021.1904894] [Reference Citation Analysis]
15 Alfonso F, Cuesta J, Rivero F. Coronary bioresorbable vascular scaffolds: requiescant in pace? Rev Esp Cardiol (Engl Ed) 2021;74:569-72. [PMID: 33622635 DOI: 10.1016/j.rec.2020.11.018] [Reference Citation Analysis]
16 Peng X, Qu W, Jia Y, Wang Y, Yu B, Tian J. Bioresorbable Scaffolds: Contemporary Status and Future Directions. Front Cardiovasc Med 2020;7:589571. [PMID: 33330651 DOI: 10.3389/fcvm.2020.589571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wiebe J, Hoppmann P, Cassese S, Rheude T, Colleran R, Kuna C, Rai H, Valeskini M, Ibrahim T, Joner M, Schunkert H, Laugwitz K, Kastrati A, Byrne RA. Evolución de pacientes tratados con armazones coronarios bioabsorbibles liberadores de everolimus tras su disolución completa. Revista Española de Cardiología 2021;74:584-90. [DOI: 10.1016/j.recesp.2020.06.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Stone GW, Maehara A, Ali ZA, Held C, Matsumura M, Kjøller-Hansen L, Bøtker HE, Maeng M, Engstrøm T, Wiseth R, Persson J, Trovik T, Jensen U, James SK, Mintz GS, Dressler O, Crowley A, Ben-Yehuda O, Erlinge D; PROSPECT ABSORB Investigators. Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. J Am Coll Cardiol 2020;76:2289-301. [PMID: 33069847 DOI: 10.1016/j.jacc.2020.09.547] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 34.0] [Reference Citation Analysis]
19 Serruys PW, Ono M, Garg S, Hara H, Kawashima H, Pompilio G, Andreini D, Holmes DR Jr, Onuma Y, King Iii SB. Percutaneous Coronary Revascularization: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol 2021;78:384-407. [PMID: 34294273 DOI: 10.1016/j.jacc.2021.05.024] [Reference Citation Analysis]
20 Kereiakes DJ. “Leave Nothing Behind”. JACC: Cardiovascular Interventions 2020;13:2850-2. [DOI: 10.1016/j.jcin.2020.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M, Shahim B, Leon MB, Bangalore S, Stone GW, Ahmad Y. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2021;42:2643-54. [PMID: 34002202 DOI: 10.1093/eurheartj/ehab280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Madhavan MV, Stone GW. Adverse events beyond 1 year after percutaneous coronary intervention. Current Opinion in Cardiology 2020;35:687-96. [DOI: 10.1097/hco.0000000000000792] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Buono A, Ielasi A, Colombo A. Latest generation stents: is it time to revive the bioresorbable scaffold? Minerva Cardioangiol 2020;68. [DOI: 10.23736/s0026-4725.20.05188-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Poulis N, Zaytseva P, Gähwiler EKN, Motta SE, Fioretta ES, Cesarovic N, Falk V, Hoerstrup SP, Emmert MY. Tissue engineered heart valves for transcatheter aortic valve implantation: current state, challenges, and future developments. Expert Review of Cardiovascular Therapy 2020;18:681-96. [DOI: 10.1080/14779072.2020.1792777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]